A recent publication in Nature Scientific Reports entitled Development of surface engineered antigenic exosomes as vaccines for respiratory syncytial virus detailed an investigation into a potential vaccine platform against respiratory syncytial virus (RSV) that used Clara Biotech’s ExoRelease™ purification system to capture and isolate exosomes which were then surface engineered and harvested.
This study, led by Dr. Suyeon Hong, implemented novel immunomagnetic nanographene particles (described as NanoPoms) to isolate exosomes which were subsequently engineered with two peptides from RSV. The authors indicated that the engineered exosomes isolated with the ExoRelease system showed much purer quality and narrower size distribution than exosomes isolated with traditional ultracentrifugation methods. Though the exosomes successfully activated the desired T cell response outside of the body, they were not yet successful at activating the desired response inside the body. However, the engineered exosomes, administered in a mouse model of RSV, appeared to be safe and well tolerated upon subcutaneous injection.The authors concluded that surface engineered exosomes, which were isolated using the ExoRelease system, are potentially promising as a vaccine platform warranting further research.
“This is the first time that the ExoRelease technology has been used to produce an exosome vaccine,” said Jim West, CEO. “We are thrilled that Clara Biotech’s technology, which is the only immunocapture and release platform to isolate and purify exosomes, will enable new vaccines as well as next generation biotech products.”
The original publication is available at the following link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560785
About Clara Biotech
Clara Biotech was founded in 2018 by James E West III, engineer and entrepreneur, and Dr. Mei He, exosome expert and assistant professor at the University of Florida. Clara Biotech has developed novel methods to isolate and purify exosomes. Its non-chemical ExoRelease™ platform uses proprietary immunocapture and release technology to exclusively isolate exosomes. The ExoRelease™ platform provides a simple, reproducible, time-saving protocol and has the same process for multiple bio-sample types. This yields pure, completely functional, in-tact, and subtyped exosomes. Clara Biotech is in the early stages of commercializing an ExoRelease™ lab kit for Research Use Only.